Glenmark Generics Ltd's US subsidiary (GGI) has notified that the company has started distribution of Morphine Sulfate Oral Concentrate Solution in the U.S. market through a licensing pact with a U.S. based pharmaceutical development company. 

The latest introduction will be the fifth product offered by Glenmark in the segment of pain management.

The company will market Morphine Sulfate Oral Concentrate Solution in three presentations, which is indicative for the relief of severe acute and severe chronic pain.

According to IMS Health data, total sales of morphine sulfate in the country for the 12 month period ending June 2008 were in excess of USD 15 million.

The product launch complements Glenmark's presently established portfolio of both oral solid and oral liquid pain management products. 

Glenmark's current portfolio consists of 36 products authorized for distribution in the
U.S. marketplace. The Company has 40 ANDA's in various stages of the approval process with the U.S. FDA. 

Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited.